Ventricular remodeling in the context of hypertensive heart disease (ventricular hypertrophy) and following myocardial infarction or congestive heart failure (ventricular dilatation) is an adverse, progressive process with a poor prognosis, and should now be included as a treatment target in these conditions. Antihypertensive treatment should be more vigorous, so as to achieve true normalization of blood pressure and regression of ventricular hypertrophy. Patients with ventricular systolic dysfunction following myocardial infarction should receive angiotensinconverting enzyme (ACE)–inhibitor treatment as part of standard therapy to prevent progressive ventricular dilatation and dysfunction and improve long-term outcomes. In congestive heart failure, combination of neurohormonal blockade with ACE-inhibitor and ß-blocker therapy provides additive benefits in improving ventricular remodeling and survival...